Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 29, 2020 07:20 ET | Source: TG Therapeutics, Inc.

TG Therapeutics Bolsters Board of Directors with the Appointment of Sagar Lonial, MD

NEW YORK, April 29, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the appointment of Sagar Lonial, MD, FACP, to the Company’s Board of Directors. Dr. Lonial has...
March 09, 2020 08:00 ET | Source: TG Therapeutics, Inc.

TG Therapeutics Announces Data Presentations at the Upcoming American Academy of Neurology 72nd Annual Meeting

NEW YORK, March 09, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that abstracts featuring ublituximab, the Company’s novel, glycoengineered anti-CD20 monoclonal...
March 05, 2020 11:00 ET | Source: TG Therapeutics, Inc.

TG Therapeutics Receives Orphan Drug Designation for Umbralisib from the U.S. Food and Drug Administration for the Treatment of Follicular Lymphoma

NEW YORK, March 05, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that the U.S. Food and Drug Administration (FDA) granted orphan drug designation to umbralisib, the...
March 03, 2020 07:00 ET | Source: TG Therapeutics, Inc.

TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2019 Financial Results

NEW YORK, March 03, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the fourth quarter and year ended December 31, 2019 and recent company...
February 28, 2020 07:30 ET | Source: TG Therapeutics, Inc.

TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2019 Financial Results and Business Update

NEW YORK, Feb. 28, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held on Tuesday March 3, 2020 at 8:00 AM ET to discuss results for...
January 16, 2020 07:30 ET | Source: TG Therapeutics, Inc.

TG Therapeutics Initiates Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration for Umbralisib as a Treatment for Patients with Previously Treated Marginal Zone Lymphoma or Follicular Lymphoma

TG received guidance from the FDA allowing submission of a single NDA for Marginal Zone Lymphoma (MZL) and Follicular Lymphoma indications Completion of rolling submission for the MZL/FL NDA...
January 10, 2020 07:30 ET | Source: TG Therapeutics, Inc.

TG Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

NEW YORK, Jan. 10, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer, will present at...
December 23, 2019 07:30 ET | Source: TG Therapeutics, Inc.

TG Therapeutics Announces $50.0 Million Registered Direct Public Offering of Common Stock to a Single Institutional Investor

NEW YORK, Dec. 23, 2019 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced it has entered into a definitive agreement to sell approximately 5.4 million shares of registered...
December 09, 2019 08:00 ET | Source: TG Therapeutics, Inc.

TG Therapeutics Announces Phase I Data Presentation for TG-1701, a Once-Daily BTK Inhibitor, as a Single Agent and in Triple Combination with Ublituximab and Umbralisib (U2), at the 61st American Society of Hematology Annual Meeting and Exposition

Proprietary triplet of U2 plus TG-1701 (BTK inhibitor) induced 86% ORR (6 of 7) in patients with relapsed/refractory NHL and CLL at the lowest dose of TG-1701 tested Single agent TG-1701 induced...
December 08, 2019 09:00 ET | Source: TG Therapeutics, Inc.

TG Therapeutics Announces Oral Presentation of Umbralisib, Ublituximab and Venetoclax Triple Combination Phase I/II Data in Relapsed/Refractory CLL at the 61st American Society of Hematology Annual Meeting and Exposition

100% overall response rate (ORR) in relapsed/refractory CLL patients treated with U2 (umbralisib + ublituximab) plus venetoclax at cycle 7 (n=13) 100% of patients (n=9) achieved undetectable MRD in...